Tower Research Capital (TRC)’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-13,771
| Closed | -$938K | – | 6927 |
|
|
2022
Q3 | $938K | Sell |
13,771
-1,211
| -8% | -$66.8K | 0.02% | 731 |
|
|
2022
Q2 | $479K | Buy |
14,982
+7,123
| +91% | +$209K | 0.01% | 1164 |
|
|
2022
Q1 | $273K | Buy |
7,859
+562
| +8% | +$16.8K | ﹤0.01% | 1524 |
|
|
2021
Q4 | $213K | Sell |
7,297
-1,364
| -16% | -$42.3K | ﹤0.01% | 1727 |
|
|
2021
Q3 | $221K | Buy |
8,661
+6,092
| +237% | +$179K | 0.01% | 1724 |
|
|
2021
Q2 | $90K | Buy |
2,569
+1,842
| +253% | +$71.9K | ﹤0.01% | 2517 |
|
|
2021
Q1 | $30K | Sell |
727
-12,092
| -94% | -$556K | ﹤0.01% | 3577 |
|
|
2020
Q4 | $555K | Buy |
12,819
+10,606
| +479% | +$523K | 0.02% | 912 |
|
|
2020
Q3 | $122K | Sell |
2,213
-13,064
| -86% | -$830K | ﹤0.01% | 2991 |
|
|
2020
Q2 | $964K | Buy |
+15,277
| New | +$1.05M | 0.04% | 550 |
|
|
2020
Q1 | – | Sell |
-4,888
| Closed | -$389K | – | 4223 |
|
|
2019
Q4 | $389K | Buy |
4,888
+2,713
| +125% | +$161K | 0.03% | 358 |
|
|
2019
Q3 | $106K | Sell |
2,175
-1,265
| -37% | -$65.9K | 0.01% | 1318 |
|
|
2019
Q2 | $181K | Buy |
3,440
+3,338
| +3,273% | +$192K | 0.01% | 892 |
|
|
2019
Q1 | $5K | Sell |
102
-758
| -88% | -$37.2K | ﹤0.01% | 3115 |
|
|
2018
Q4 | $35K | Sell |
860
-763
| -47% | -$28.6K | ﹤0.01% | 1542 |
|
|
2018
Q3 | $62K | Buy |
1,623
+437
| +37% | +$19.4K | ﹤0.01% | 1632 |
|
|
2018
Q2 | $54K | Sell |
1,186
-281
| -19% | -$12.8K | ﹤0.01% | 1815 |
|
|
2018
Q1 | $71K | Buy |
1,467
+445
| +44% | +$24.8K | 0.01% | 1477 |
|
|
2017
Q4 | $40K | Buy |
1,022
+955
| +1,425% | +$35.7K | 0.01% | 1510 |
|
|
2017
Q3 | $2K | Sell |
67
-774
| -92% | -$21.8K | ﹤0.01% | 3611 |
|
|
2017
Q2 | $23K | Buy |
+841
| New | +$25K | ﹤0.01% | 1153 |
|
|
2017
Q1 | – | Sell |
-200
| Closed | -$3K | – | 4164 |
|
|
2016
Q4 | $3K | Buy |
+200
| New | +$3.51K | ﹤0.01% | 3317 |
|
|
2016
Q3 | – | Sell |
-1,331
| Closed | -$22K | – | 4721 |
|
|
2016
Q2 | $22K | Buy |
1,331
+189
| +17% | +$3.81K | ﹤0.01% | 2174 |
|
|
2016
Q1 | $18K | Buy |
1,142
+1,077
| +1,657% | +$19.1K | ﹤0.01% | 1451 |
|
|
2015
Q4 | $2K | Sell |
65
-2,265
| -97% | -$98.1K | ﹤0.01% | 3858 |
|
|
2015
Q3 | $99K | Buy |
+2,330
| New | +$110K | 0.01% | 579 |
|
Other funds holding GBT
Tower Research Capital (TRC)'s GBT Position: Q4 2022 in Review
Tower Research Capital (TRC) sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 13,771 shares — an estimated $938K sold.
Tower Research Capital (TRC) first reported a position in GBT in Q3 2015 and held it in 26 quarters. The position peaked at $964K in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Tower Research Capital (TRC) reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 13,771 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $938K.
- Tower Research Capital (TRC) first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 26 quarters.
- Tower Research Capital (TRC)'s Global Blood Therapeutics, Inc. position peaked at $964K in Q2 2020.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.